Novel systemic drugs for cutaneous T-cell lymphoma

For the last few years new therapeutic options for primary cutaneous T-cell lymphoma (CTCL) have been recently introduced into clinical trials, particularly for patients with advanced stage and refractory disease. Systemic treatment uses biological response modifiers, such as fusion molecules, rexin...

Full description

Saved in:
Bibliographic Details
Published inRecent patents on anti-cancer drug discovery Vol. 6; no. 1; p. 70
Main Authors Lech-Maranda, Ewa, Robak, Ewa, Robak, Tadeusz
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2011
Subjects
Animals
Antineoplastic Agents - administration & dosage
Drugs, Investigational - administration & dosage
Histone Deacetylase Inhibitors - administration & dosage
Histone Deacetylase Inhibitors - therapeutic use
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - therapeutic use
Injections, Intravenous
Lymphoma, T-Cell - drug therapy
Models, Biological
Skin Neoplasms - drug therapy
Online AccessGet more information

Cover

More Information
Summary:For the last few years new therapeutic options for primary cutaneous T-cell lymphoma (CTCL) have been recently introduced into clinical trials, particularly for patients with advanced stage and refractory disease. Systemic treatment uses biological response modifiers, such as fusion molecules, rexinoids, interferons as well as monoclonal antiobodies, and new antiproliferative drugs, such as histone deacetylase inhibitors, proteasome inhibitors or forodesine. This review focuses on recent advances in the development of systemic agents for CTCL including both novel patented compounds and novel therapeutic protocol of intervention.
ISSN:2212-3970
DOI:10.2174/157489211793980051